Amyloid Beta A4 Precursor Protein-Binding Family (APP-BP): A novel Drug Target and Biomarker

Target Name: Amyloid beta A4 precursor protein-binding family (APP-BP)

NCBI ID: P11250

Amyloid beta A4 precursor protein-binding family (APP-BP)

Other Name(s): APP-BP

Amyloid Beta A4 Precursor Protein-Binding Family (APP-BP): A novel Drug Target and Biomarker

Introduction

Amyloid beta (A尾) is a highly aggregating protein that is derived from the amyloid precursor protein (APP). A尾 is involved in the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other forms of dementia. The discovery of APP as a potential drug target has led to the development of numerous compounds that aim to inhibit A尾 formation and its aggregation. However, many of these compounds have been shown to be less effective than beneficial because they cannot specifically bind A尾42, And other adverse reactions may occur. Therefore, studying new and specific APP-BP ligands has important theoretical and practical value.

Amyloid Beta A4 Precursor Protein-Binding Family (APP-BP)

APP-BP is a conserved protein family consisting of A尾42, A尾40 and A尾30. APP-BP has a highly conserved amino acid sequence and plays important biological functions in cells. The protein domain of APP-BP contains multiple specific interaction sites that can interact with various molecules, including A尾42.

The biological functions of APP-BP are closely related to the biological functions of A尾42. A尾42 is a part of APP, which is modified by 尾-1,4-glycosylation from A尾40 and A尾30. The biological functions of A尾42 include participation in cell signaling, cell adhesion, cell migration and cell proliferation. Studies have shown that APP-BP can specifically bind A尾42 and inhibit the aggregation and intracellular spread of A尾42.

Drug target properties of APP-BP

As a drug target, APP-BP has high specificity and safety. First, the content of APP-BP in cells is lower, which reduces the side effects caused by the drug in the body. In addition, APP-BP expresses relatively few proteins, which reduces drug damage to normal cells. These characteristics make APP-BP a very promising drug target.

Biological activity of APP-BP

APP-BP has a variety of biological activities, including anti-neuroinflammation, antioxidant, anti-tumor and anti-apoptosis. The biological activity of APP-BP is closely related to its specific amino acid sequence. On this basis, researchers can speculate on the pharmacological mechanism of APP-BP.

Clinical application prospects of APP-BP

As a new drug target, APP-BP has broad clinical application prospects. First, APP-BP could be used to treat patients with various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and other forms. Secondly, APP-BP can be used to treat various cancers, such as breast cancer, lung cancer, and prostate cancer. APP-BP can also be used to treat neuroinflammation, such as Parkinson's disease and Alzheimer's disease.

Conclusion

Amyloid beta (A尾) is a highly aggregating protein that is derived from the amyloid precursor protein (APP). A尾 is involved in the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other forms of dementia. The discovery of APP as a potential drug target has led to the development of numerous compounds that aim to inhibit A尾 formation and its aggregation. However, many of these compounds have been shown to be less effective than beneficial because they cannot specifically bind A尾42, And other adverse reactions may occur. Therefore, studying new and specific APP-BP ligands has important theoretical and practical value. As a new drug target, APP-BP has high specificity and safety, and can provide new treatment methods and ideas for the treatment of various neurodegenerative diseases, cancer and neuroinflammation.

Protein Name: Amyloid Beta A4 Precursor Protein-binding Family (APP-BP) (nonspecified Subtype)

The "Amyloid beta A4 precursor protein-binding family (APP-BP) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Amyloid beta A4 precursor protein-binding family (APP-BP) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets